Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Metabolic Profiles of Montelukast Sodium (Singulair), a Potent Cysteinyl Leukotriene1 Receptor Antagonist, in Human Plasma and Bile

S. K. Balani, X. Xu, V. Pratha, M. A. Koss, R. D. Amin, C. Dufresne, R. R. Miller, B. H. Arison, G. A. Doss, M. Chiba, A. Freeman, S. D. Holland, J. I. Schwartz, K. C. Lasseter, B. J. Gertz, J. I. Isenberg, J. D. Rogers, J. H. Lin and T. A. Baillie
Drug Metabolism and Disposition November 1997, 25 (11) 1282-1287;
S. K. Balani
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
X. Xu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
V. Pratha
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. A. Koss
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. D. Amin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. Dufresne
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. R. Miller
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
B. H. Arison
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G. A. Doss
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Chiba
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. Freeman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. D. Holland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. I. Schwartz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
K. C. Lasseter
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
B. J. Gertz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. I. Isenberg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. D. Rogers
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. H. Lin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
T. A. Baillie
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Montelukast sodium [1-{[(1(R)-(3-(2-(7-chloro-2-quinolinyl)-(E)- ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio]methyl}cyclopropylacetic acid sodium salt] (MK-476, Singulair) is a potent and selective antagonist of the cysteinyl leukotriene (Cys-LT1) receptor and is under investigation for the treatment of bronchial asthma. To assess the metabolism and excretion of montelukast, six healthy subjects received single oral doses of 102 mg of [14C]montelukast, and the urine and feces were collected. Most of the radioactivity was recovered in feces, with ≤0.2% appearing in urine. Based on these results and the reported modestly high oral bioavailability of montelukast, it could be concluded that a major part of the radioactivity was excretedvia bile. A second clinical study was conducted to identify biliary metabolites of montelukast. The bile was aspirated using a modified procedure involving a nasogastric tube placed fluoroscopically near the ampulla of Vater, after an oral dose of 54.8 mg of [14C]montelukast. This technique appears to be a new application for drug metabolism studies. The study was conducted with fasted and nonfasted subjects, with the bile being aspirated continuously under suction over periods of 2–8 hr and 8–12 hr after the dose, respectively. Two hours before the end of the collection procedure, cholecystokinin carboxyl-terminal octapeptide was administered iv to stimulate gallbladder contraction. Plasma samples also were collected periodically over 10 hr. Due to the nature of the collection procedure and the limited sampling time, recovery of radioactivity in bile was incomplete and varied from 3 to 20% of the dose. Radiochromatographic and LC-MS/MS analyses of bile showed the presence of one major and several minor metabolites, along with small amounts of unchanged parent drug. The minor metabolites were identified, by LC-MS/MS comparison with synthetic standards or by NMR, as acyl glucuronide (M1), sulfoxide (M2), 25-hydroxy (a phenol, M3), 21-hydroxy (diastereomers of a benzylic alcohol, M5a and M5b), and 36-hydroxy (diastereomers of a methyl alcohol, M6a and M6b) analogs of montelukast. The major metabolite was characterized as a dicarboxylic acid (M4), a product of further oxidation of the hydroxymethyl metabolite M6. Chiral LC-MS/MS analyses of M4 revealed that this diacid, like M5 and M6, was formed in both diastereomeric forms. The levels of metabolites in the systemic circulation were low in the fed as well as fasted subjects, with <2% of the circulating radioactivity being due to metabolites M5a, M5b, M6a, and M6b. Overall, this bile aspiration technique, which is less invasive than either T-tube drainage or fine-needle percutaneous puncture, provided a convenient and expedient means of identifying the biliary metabolites of montelukast, relatively free of contributions from colonic microflora.

Footnotes

  • Send reprint requests to: Suresh K. Balani, Ph.D., Department of Drug Metabolism, Merck Research Laboratories, WP44B-100, West Point, PA 19486.

  • Abbreviations used are::
    Cys
    cysteinyl
    LT
    leukotriene
    • Received April 2, 1997.
    • Accepted July 15, 1997.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition
Vol. 25, Issue 11
1 Nov 1997
  • Table of Contents
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Metabolic Profiles of Montelukast Sodium (Singulair), a Potent Cysteinyl Leukotriene1 Receptor Antagonist, in Human Plasma and Bile
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Metabolic Profiles of Montelukast Sodium (Singulair), a Potent Cysteinyl Leukotriene1 Receptor Antagonist, in Human Plasma and Bile

S. K. Balani, X. Xu, V. Pratha, M. A. Koss, R. D. Amin, C. Dufresne, R. R. Miller, B. H. Arison, G. A. Doss, M. Chiba, A. Freeman, S. D. Holland, J. I. Schwartz, K. C. Lasseter, B. J. Gertz, J. I. Isenberg, J. D. Rogers, J. H. Lin and T. A. Baillie
Drug Metabolism and Disposition November 1, 1997, 25 (11) 1282-1287;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Metabolic Profiles of Montelukast Sodium (Singulair), a Potent Cysteinyl Leukotriene1 Receptor Antagonist, in Human Plasma and Bile

S. K. Balani, X. Xu, V. Pratha, M. A. Koss, R. D. Amin, C. Dufresne, R. R. Miller, B. H. Arison, G. A. Doss, M. Chiba, A. Freeman, S. D. Holland, J. I. Schwartz, K. C. Lasseter, B. J. Gertz, J. I. Isenberg, J. D. Rogers, J. H. Lin and T. A. Baillie
Drug Metabolism and Disposition November 1, 1997, 25 (11) 1282-1287;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • TMDD Affects PK of IL-10 Fc-fusion Proteins
  • Uptake as the RDS in Pevonedistat Hepatic Clearance
  • In vitro downregulation of OATP1B1 by retinoids
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics